Dive Brief:
Pfizer's Duchenne muscular dystrophy gene therapy improved physical function in two patients measured one year after treatment, but also led to one patient being...
Lartruvo (olaratumab) was the first new drug approved for soft tissue sarcoma in more than four decades, at the time offering patients with the tough-to-treat...
In gene therapy, where dramatic results in deadly diseases can hasten clinical testing, studies tend to be smaller, with greater significance put on each...
Denali started 2018 with one research agreement with Takeda and is now ending the year with another big pharma collaboration.
The Takeda deal, announced in...
The plaques are considered hallmarks of Alzheimer's disease, formed in the brain from sticky clusters of a misfolded protein fragment called beta-amyloid.
For the past...
PHILADELPHIA — It's not artificial intelligence or creative corporate structures that some of the biopharma industry's leaders see as the best way to boost...
Long known for its prowess in cardiovascular and respiratory diseases, AstraZeneca has joined its pharmaceutical peers in making a bigger play in oncology.
While the...
Wave Life Sciences has joined the biopharma sector's gold rush to treat DMD, a genetic disorder that causes progressive musculoskeletal disability in boys.
So far,...
The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...
Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...
